What is "patent linkage"? — resolving disputes at registration
The traditional model was "launch first, litigate later": a generic launches, and the originator sues for infringement. The problem — once a generic is already distributed across thousands of hospitals and pharmacies, even a winning judgement rarely achieves effective market exclusion.
Patent linkage moves the resolution point from post-launch to pre-launch: a generic filing an ANDA must address the originator's patents at the same time, so the dispute is triggered and resolved before market entry.
The patent-linkage process, step by step
- Originator registers patents: within 30 days of approval, list relevant patents on the registration platform (the "Orange Book").
- Generic files and declares: submit the ANDA and make a P1/P2/P3/P4 declaration for each listed patent.
- P4 notification: the generic notifies the originator MAH in writing within 10 working days, with the key technical points.
- The 45-day window: the originator has 45 days to sue at the Beijing IP Court or seek a CNIPA administrative ruling.
- The 9-month stay: if the originator sues within 45 days, CDE pauses technical review for up to 9 months pending the decision.
- Effect on ANDA review: patent upheld and infringed → ANDA not approved until expiry; patent invalidated or not infringed → review continues.
- First-generic exclusivity: the first successful challenger wins 12 months of market exclusivity.
The P4 declaration — the generic's core weapon
A P4 declaration chooses a high-risk, high-reward path: challenging the validity of the originator's patent or asserting non-infringement.
Two legal paths for P4
- Path A — invalidation: arguing the listed patent fails patentability (novelty, inventiveness, insufficient disclosure) via a request to CNIPA.
- Path B — non-infringement: arguing the generic does not fall within the patent claims (no literal or equivalent infringement), via a declaratory action at the Beijing IP Court or a defence in the originator's suit.
Strategy: before a P4 declaration, run a thorough FTO analysis and patent-stability assessment. If the chance of invalidation is under 50% or a design-around is impractical, an ill-considered P4 can end in defeat — the ANDA fails and the generic bears the originator's costs and possible damages. P4 is a double-edged sword requiring precise judgement.
The 12-month first-generic exclusivity — the crown jewel
This is the system's most commercially valuable feature. The first generic to successfully challenge the originator's patent and win ANDA approval enjoys 12 months of market exclusivity as the only generic of that product on the market — enjoying "oligopoly pricing" while the originator still sells.
- Start date: 12 months from the first generic's ANDA approval.
- Excluded applications: other same-product generics' ANDAs, regardless of their own P4 declarations.
- Shared exclusivity: if multiple generics are approved the same day and all qualify, they share the 12 months (each does not get its own).
How we help
- For originators: Orange Book registration strategy, assessment of P4 notices, the within-45-days decision to sue, infringement litigation at the Beijing IP Court, and defence against counterclaims.
- For generics: FTO search and patent-stability analysis, P1–P4 strategy, invalidation or declaratory non-infringement actions after P4, and pursuit and maintenance of first-generic exclusivity.